DeciBio

We're excited to kick off the new year with the inaugural Women of Precision Medicine: 25 Perspectives for 2025! This list features 25 exceptional women making an impact as leaders in precision medicine. From women’s health to cancer detection, digital pathology, AI, and beyond, their perspectives address key themes like diagnostic accessibility, equity in genomics, and the promise of multi-omics, emphasizing the transformative contributions of women across the field. This initiative was developed with the contributions of Tina Wang, Katie Maloney, Mané Mikayelyan, Megan Nacar, Kimmi Stacey, and Stephane Budel, whose efforts reflect a shared commitment to amplifying women’s voices and driving meaningful progress in precision medicine. Explore the publication and learn more about how to nominate a WOPM for future initiatives here: https://lnkd.in/gRZxwqFT #WOPM #Leadership #PrecisionMedicine

Our #MeetTheTeam series continues! Meet our Vice President of Commercial, Megan Nacar. Megan brings over a decade of experience working on the commercial side of diagnostics, from pathology to clinical bioinformatics and next-generation sequencing. She plays a key role in shaping how we position DeciBio’s strategy work and market intelligence, ensuring our insights resonate with the industry and drive meaningful impact. From helping craft our thought leadership to fostering connections with key stakeholders, Megan helps bring our expertise to the forefront of precision medicine. But beyond her expertise, every member of our team brings a unique element of their personality to DeciBio. For Megan, that means sharing her passion for Formula 1—sparking discussions on strategy, precision, and maybe even a little friendly debate on race weekends. We believe the best teams thrive when they connect beyond the work they do, building on shared interests and diverse perspectives. ?? #CareersAtDeciBio

At Precision Med TRI-CON 2025, David Cavanaugh took the stage to discuss one of the most pressing topics in diagnostics: how new regulations could reshape the landscape for LDTs. Key points included balancing innovation with regulatory compliance; potential effects on patient access to novel tests; and the impact on rare disease testing and oncology diagnostics. Missed the session or want to connect on this topic? Contact our team of experts! #TriCon2025 #LDTregulation #PrecisionMedicine

Last week’s International Women’s Day Event was a powerful reminder of the importance of taking up space, sharing expertise, and shaping the conversations that define our industries. We’re proud to have women like Tina Wang and Megan Nacar at DeciBio who are making an impact in this space and beyond. Looking forward to continuing these important conversations! #InternationalWomensDay #WomenInLeadership #WomenInConsulting #PrecisionMedicine

We are proud members of the The Alliance for Artificial Intelligence in Healthcare (AAIH) - thank you for sharing our IWD event from last Thursday! #IWD #WomensHistoryMonth

March is a time to reflect on the contributions of women in science and healthcare, and what better way to do that than by revisiting our Women of Precision Medicine: 25 Perspectives for 2025 initiative? This list highlights 25 outstanding women who are advancing precision medicine and challenging the status quo. From expanding access to genomic testing and integrating AI into diagnostics to pioneering new approaches in cancer screening and women’s health, their insights offer a glimpse into the future of the field. As we celebrate Women's History Month, we invite you to explore their insights and nominate women who continue to drive impact in this space. Who are the women in precision medicine inspiring you? Read the full publication and submit nominations here: https://lnkd.in/gRZxwqFT #WomensHistoryMonth #WOPM #Leadership #PrecisionMedicine

The DeciBio team is heading to the 32nd International Precision Med TRI-CON this week, and we’re bringing three expert speakers to the stage. If you're attending, don’t miss these insightful sessions: Speaking Sessions: ? Rebecca Burnham, PhD – Spatial Biology: Market Projections, Clinical Applications, and Future Trends (March 11, 1:25 PM) ? David Cavanaugh – The Future of Precision Medicine under New LDT Regulation (March 12, 2:35 PM) ? Luka Jelcic – AI-Driven Precision Medicine in Autoimmune Disorders (March 13, 11:30 AM) If you’ll be at Tri-Con, we’d love to connect. Reach out to schedule a meeting or join us for these discussions. See you there! #PrecisionMedicine #TriCon2025 #AIinHealthcare #SpatialBiology #LDTRegulation

? February brought plenty of #LBx news, including numerous partnerships and collaborations, fundraising, and study data.?? ? Clinical and Regulatory? Natera announced that its Signatera test has received coverage from the Centers for Medicare & Medicaid Services (CMS) Molecular Diagnostics Services Program (MolDX) for NSCLC patients. ClearNote Health announced that their Avantect Pancreatic Cancer Test has been approved by the New York State Department of Health, making it available to clinicians in New York as a tool for pancreatic cancer early detection (EDx). Labcorp also launched its new Plasma Complete ctDNA CGP solution last month, designed to guide treatment decisions for advanced tumors.? ? Company Announcements & Product Launches? Foresight Diagnostics announced the expansion of their strategic collaboration with Allogene Therapeutics. Lynx Dx has launched ordering of its MyProstateScore 2.0 test’s at-home collection format. The test is ordered by physicians and is eligible for Medicare reimbursement. Meanwhile, Flatiron Health and Exact Sciences have announced a new collaboration aimed at generating clinical evidence for Exact’s MRD test, called Oncodetect, across a range of solid tumors. The first patient has already been enrolled.? ? Clinical Trials & Study Results? Researchers from the University of Washington and Fred Hutchinson Cancer Center have demonstrated the value of a prenatal cfDNA WGS assay for predicting preeclampsia. The test achieved 81% and 79% sensitivity in validation and external cohort analysis, respectively. A new pancreatic ductal adenocarcinoma (PDAC) assay was developed at Oregon Health & Science University. ? M&A | VC | Private Equity | Legal? PacBridge Capital Partners has backed AI health tech startup Avitia with $5M in seed funding. Avitia’s technology aims to enable cancer centers to perform NGS tests in-house, thereby improving affordability and accessibility. Syantra Inc. has received funding from Alberta Innovates to expand clinical studies of its Onco-ID: Breast screening test. The funding complements funding from the US DoD and will support a pilot study at the Mays Cancer Center at UT Health San Antonio. Oncocyte Corporation has raised $29.1M through concurrent offering to existing investors and private placements to fund its FDA IVD transplant assay program.? ? ? Read the newsletter for more:??https://lnkd.in/gGueNDjq ? Sign up to receive our Liquid Biopsy Newsletter in your email:?https://lnkd.in/gKQn7_zp ? The headlines have been handcrafted by Amal Thommil, Graham F., Nila Venkat, and Antony Awad?? ? #cancerdetection #earlydetection #precisionmedicine #productlaunches #cancermonitoring #liquidbiopsytesting?

What an experience! This past Friday, Team DeciBio - NYC took to the Bryant Park Cycle for Survival event, to join the fight against cancer. For those unfamiliar, Cycle for Survival is a global fundraising initiative led by Memorial Sloan Kettering Cancer Center (MSKCC) and Equinox to support rare cancer research. With MSK's extensive medical reach - over 2000 ongoing clinical trials tackling nearly 400 types of cancer - paired with Equinox's global infrastructure, this collaboration has been able to raise over $400 million since its inception in 2007. It's exciting to see MSK continue to form partnerships like this and the SOPHiA Genetics liquid biopsy initiative; both are helping to expand access to and adoption of life-changing cancer diagnostics and treatments. Big shoutout to my team on the ground Kimmi Stacey, Sylvia Illouz, and Alexander Nguyen, along with Megan Nacar for pushing us to participate. Looking forward to next year!

Happy International Women’s Day from DeciBio’s Women in Consulting Group! At DeciBio, our Women in Consulting (WIC) group is committed to fostering professional growth, accountability, and leadership within the firm and across the broader precision medicine industry. We meet regularly to set ambitious goals, champion each other’s success, and drive initiatives that create meaningful change. One of our key priorities last year was to see more women in leadership roles at the firm. Since then, we’ve proudly announced Katie Maloney as a Partner, a milestone that reflects our commitment to cultivating female leadership at DeciBio. But our efforts extend beyond our own walls—we’re also dedicated to amplifying the voices of women driving innovation across the industry. This commitment led to our latest initiative, Women of Precision Medicine, a curated list celebrating 25 women making a transformative impact in precision medicine. These leaders sit at the highest levels of their organizations, shaping the future of healthcare through groundbreaking work in genomics, diagnostics, bioinformatics, and beyond. You can read more about that initiative here: https://lnkd.in/gDbb2X7S We know that representation matters—not just in leadership, but in the voices that shape the industry’s trajectory. Today, we celebrate these remarkable women, our colleagues, and all those breaking barriers in STEM and healthcare. #InternationalWomensDay #WomenInLeadership #WomenInConsulting #WomenInPrecisionMedicine #DeciBio